COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026.
StrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundariesWhole-transcriptome profiling across a large tissue capture area...
MANASSAS, Va., June 6, 2026 /PRNewswire/ -- PureHealth Research today pointed to the growing scientific interest in naturally sourced peptide nutrition for healthy aging...
Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978
SHANGHAI, June 5, 2026 /PRNewswire/ -- LongBio Pharma, a portfolio company of Qiming Venture Partners and a leading innovative drug developer for allergic and...
SHANGHAI, June 5, 2026 /PRNewswire/ -- LongBio Pharma, a portfolio company of Qiming Venture Partners and a leading innovative drug developer for allergic and...
LONDON, June 04, 2026 (GLOBE NEWSWIRE) -- London Specialist Dentists has announced the use of medical-grade Ozone Therapy as part of its advanced approach to periodontal treatment, dental implant care, and minimally invasive gum therapy.
Zydus Hospitals Ahmedabad and Vadodara reach new heights in advanced transplant care AHMEDABAD, India, June 4, 2026 /PRNewswire/ -- Organ transplantation in India has come a...
Tokyo, Japan and Cambridge, UK, 2 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation to vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The Company plans to submit a Marketing Authorization Application (MAA) for vamorolone in South Korea during 2026.
BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a pioneering clinical stage biotechnology company at the forefront of oxygen therapeutics, is proud to announce a major scientific milestone: the publication of Body Oxygen Homeostasis and Mitochondrial Function from Animal Models to Clinical Applications by Prof. Avraham Mayevsky, a key advisor to Bioxytran. This groundbreaking work dives deep into the science of oxygen regulation and mitochondrial health – revealing transformative insights that could redefine treatment for stroke, Alzheimer’s, and other critical conditions.
Summer Appreciation Sales Offers 12% Off All Products
NEW YORK, Aug. 15, 2025 /PRNewswire/ -- BestQool , a pioneer manufacturer of home-use red light therapy...